OR WAIT null SECS
Click here to read the articles and download the PDF
A conversation with Matthew Bardell, managing director, nVentic, about a perhaps overlooked but useful strategic component of company performance and overall business benchmarks: inventory optimization.
Making sense of the accelerating trends and challenges—including store closings, pharmacy deserts, and the rise of polypharmacy.
Even as pharma technology evolves, and payers argue over reimbursement practices throughout healthcare, drug wholesaling is a thriving business.
November 22, 2023
The CDMO’s GMP plant will dedicate 2,500 square feet to the storage of finished products.
November 21, 2023
IQVIA report explores why these shortages are increasing, and how they can be mitigated.
Medication focuses on the acute treatment of migraines.
November 20, 2023
Study emphasizes role in bridging research and development and commercial/marketing functions.
IATA numbers point to continuing recovery.
Purchase grows the company’s CRYOPDP domestic footprint while strengthening working relationship between both parties.
November 17, 2023
The FDA also approved a companion diagnostic test to detect the PIK3CA, AKT1, and PTEN alterations as part of the approval for AstraZeneca’s capivasertib (Truqap) plus fulvestrant (Faslodex) for HR-positive, HER2-negative locally advanced or metastatic breast cancer.
Enzalutamide (Xtandi) gets FDA approval to treat nonmetastatic castration-sensitive prostate cancer with biochemical recurrence at high risk for metastasis.
With new mandates right around the corner, there is an unwavering demand for pharma operations to perform at peak efficiency.
Pembrolizumab (Keytruda) plus fluoropyrimidine- and platinum-containing chemotherapy for locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction cancer approved by FDA after being found to lower the risk of metastasis or death.